Inflammatory Microenvironment of Acute Myocardial Infarction Prevents Regeneration of Heart with Stem Cells Therapy

Khodayari, Saeed; Khodayari, Hamid; Amiri, Ali Zahedi; Eslami, Maryam; Farhud, Dariush D.; Hescheler, Jürgen; Nayernia, Karim

doi:10.33594/000000180

Cited by 58 publications

(40 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimal timing of cell therapy after AMI has been investigated in several trials using BM-MSC with catheterbased applications. Myocardial microenvironment at different time points after infarction has profound influences on stem cells survival, homing and differentiation (Traverse et al, 2012;Khodayari et al, 2019). In acute infarct stage, the microenvironment is not conducive to the survival and growth of stem cells because of the overwhelming inflammatory response in the myocardial injury area.…”

Section: Imaging-guided Mini-invasive Injectionmentioning

confidence: 99%

The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease

Liu

Han

Liang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Ischemic heart disease (IHD) is the leading cause of mortality worldwide. Stem cell transplantation has become a promising approach for the treatment of IHD in recent decades. It is generally recognized that preclinical cell-based therapy is effective and have yielded encouraging results, which involves preventing or reducing myocardial cell death, inhibiting scar formation, promoting angiogenesis, and improving cardiac function. However, clinical studies have not yet achieved a desired outcome, even multiple clinical studies showing paradoxical results. Besides, many fundamental puzzles remain to be resolved, for example, what is the optimal delivery timing and approach? Additionally, limited cell engraftment and survival, challenging cell fate monitoring, and not fully understood functional mechanisms are defined hurdles to clinical translation. Here we review some of the current dilemmas in stem cell-based therapy for IHD, along with our efforts and opinions on these key issues.

show abstract

Section: Imaging-guided Mini-invasive Injectionmentioning

confidence: 99%

The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease

Liu

Han

Liang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…There was no statistical significance in the incidence of adverse drug reactions between the two groups after treatment (p=0.42). Excessive levels of inflammatory cytokines 23 and N-terminal brain natriuretic peptide (BNP) 24 will have a serious impact on the prognosis of patients with myocardial infarction. Tirofiban has been shown in some studies 25 to have anti-inflammatory activity, which can reduce further damage caused by flammatory cytokines.…”

Section: Discussionmentioning

confidence: 99%

Effect of Tirofiban Injection on vascular endothelial function, cardiac function and inflammatory cytokines in patients with acute myocardial infarction after emergency Percutaneous Coronary Intervention

Kang¹,

Meng

Li³

2021

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To evaluate the effect of tirofiban injection on vascular endothelial function, cardiac function, inflammatory cytokines and other indicators in patients with acute myocardial infarction after emergency PCI and its clinical significance. Methods: Eighty patients with acute myocardial infarction admitted to Affiliated Hospital of Hebei University from March 18, 2020 to October 18, 2020 were enrolled and randomly divided into two groups: the experimental group and the control group, with 40 cases in each group. Patients in both groups underwent PCI. Patients in the control group were given oxygen inhalation, monitoring, and basic medications for myocardial infarction, such as nutritional myocardial drugs, statins, aspirin, nitrates, clopidogrel, and β-blockers. In contrast, patients in the experimental group received tirofiban 10 ug/kg intravenously over 5min immediately before PCI in addition to basic treatment, and then tirofiban 0.1 ug/(kg/min) was pumped via intravenous pump postoperatively for 48 hour. The changes of vascular endothelial function, cardiac function and adverse drug reactions (ADRs) in the two groups before treatment, one week and one month after treatment, as well as changes of inflammatory cytokines such as CRP and IL-6 in the two groups before and after treatment were compared and analyzed. Results: Compared with the control group, FMD, NO, ET-1 and other indexes in the experimental group were significantly improved one week and one month after treatment, with statistically significant differences (p<0.05). BNP, LVEDD, LVEF and additional indexes in the experimental group were significantly lower than those in the control group at one week and one month after treatment, with statistically significant differences (p=0.00). Moreover, the incidence of ST-segment fallback > 70% in the experimental group was 72.5% after treatment, which was significantly better than that of 47.5% in the control group, with a statistically significant difference (p=0.03). CRP and IL-6 in the experimental group were significantly lower than those in the control group after treatment, with a statistically significant difference (p=0.00). There was no statistical significance in the incidence of ADRs between the two groups after treatment (p=0.42). Conclusion: Tirofiban injection after emergency PCI is a beneficial treatment regime for patients with STEMI. With such a treatment regime, cardiac function and vascular endothelial function of patients can be dramatically improved, coronary blood supply will be ameliorated, inflammatory cytokines can be reduced, and no significant increase can be seen in the incidence of adverse reactions. doi: https://doi.org/10.12669/pjms.38.1.4413 How to cite this:Kang S, Meng X, Li J. Effect of Tirofiban Injection on vascular endothelial function, cardiac function and inflammatory cytokines in patients with acute myocardial infarction after emergency Percutaneous Coronary Intervention. Pak J Med Sci. 2022;38(1):---------. doi: https://doi.org/10.12669/pjms.38.1.4413 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…The situation is even of more concern regarding the potential role of dyslipidemia, or specifically cholesterol or free fatty acids, in inducing this damage that is virtually ignored. In contrast, the noxious inflammatory milieu [28] or the senescence process [29,30] are occasionally mentioned as a risk. Tangential old citations for cholesterol damaging stem cells [31,32], or more recent for palmitate impact on progenitor cells apoptosis [33], do not seem to have yet challenged the implicit dogma of stem cell resistance to the systemic milieu.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the In Vitro Damage Caused by Lipid Factors on Stem Cells from a Female Rat Model of Type 2 Diabetes/Obesity and Stress Urinary Incontinence

Kovanecz

Gelfand

Sharifzad

et al. 2020

IJMS

View full text Add to dashboard Cite

Human stem cell therapy for type 2 diabetes/obesity (T2D/O) complications is performed with stem cell autografts, exposed to the noxious T2D/O milieu, often with suboptimal results. We showed in the Obese Zucker (OZ) rat model of T2D/O that when their muscle-derived stem cells (MDSC) were from long-term T2D/O male rats, their repair efficacy for erectile dysfunction was impaired and were imprinted with abnormal gene- and miR-global transcriptional signatures (GTS). The damage was reproduced in vitro by short-term exposure of normal MDSC to dyslipidemic serum, causing altered miR-GTS, fat infiltration, apoptosis, impaired scratch healing, and myostatin overexpression. Similar in vitro alterations occurred with their normal counterparts (ZF4-SC) from the T2D/O rat model for female stress urinary incontinence, and with ZL4-SC from non-T2D/O lean female rats. In the current work we studied the in vitro effects of cholesterol and Na palmitate as lipid factors on ZF4-SC and ZL4-SC. A damage partially resembling the one caused by the female dyslipidemic serum was found, but differing between both lipid factors, so that each one appears to contribute specifically to the stem cell damaging effects of dyslipidemic serum in vitro and T2D/O in vivo, irrespective of gender. These results also confirm the miR-GTS biomarker value for MDSC damage.

show abstract

Inflammatory Microenvironment of Acute Myocardial Infarction Prevents Regeneration of Heart with Stem Cells Therapy

Abstract: This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission.

Cited by 58 publications

References 119 publications

The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease

The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease

Effect of Tirofiban Injection on vascular endothelial function, cardiac function and inflammatory cytokines in patients with acute myocardial infarction after emergency Percutaneous Coronary Intervention

Evaluation of the In Vitro Damage Caused by Lipid Factors on Stem Cells from a Female Rat Model of Type 2 Diabetes/Obesity and Stress Urinary Incontinence

Contact Info

Product

Resources

About